Rachel Eren

Intellect Neurosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of disease-modifying therapeutic agents. It specializes in treatment and prevention of neurodegenerative conditions, collectively known as proteinopathies, which include alzheimer's, parkinson's and huntington disease. The company was founded by Daniel G. Chain on April 25, 2005 and is headquartered in Englewood Cliffs, NJ.

Andromeda Biotech Ltd. develops treatment for autoimmune diabetes. The company was founded in 2007 and is headquartered in Rehovot, Israel.

Xl Therapeutics Ltd. operates as biopharmaceutical company. It aims to develop small molecule compounds to treat patients suffering from Wiskott-Aldrich syndrome and X-linked thrombocytopenia, rare primary human immunodeficiencies that are caused by the absence and suboptimal function of the WAS protein. The company was founded in May 2016 and is headquartered in Ness Ziona, Israel.

Pink Biopharma Ltd. engages in the development of novel immune checkpoint inhibitor against a protein expressed on cancer tissue, which acts as an inhibitory ligand for natural killer cells. The company was founded by Rachel Eren, Yael Yoffe-Mizrahi, and Angel Porgador and is headquartered in Tel Aviv, Israel.